National Cancer Institute Thai Cancer Anemia Survey

This study has been completed.
Information provided by (Responsible Party):
Janssen-Cilag Ltd.,Thailand Identifier:
First received: December 10, 2009
Last updated: April 8, 2014
Last verified: April 2014
The purpose of this study is to create a large Thailand database documenting the severity of anemia and its management in the cancer population.

Condition Intervention Phase
Other: Adult Cancer Patients
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Anemia Survey in Cancer Patients Study

Resource links provided by NLM:

Further study details as provided by Janssen-Cilag Ltd.,Thailand:

Primary Outcome Measures:
  • Number of patients that have anemia during cancer therapy [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Characteristics of patients example treatment duration, type of chemotherapy used, grade of anemia [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: June 2006
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
001 Other: Adult Cancer Patients
Tracking anemia management in Adult Cancer Patients

Detailed Description:
Thai Cancer Anemia Study (TCAS) is a prospective survey that will track anemia management in an adult cancer population. This survey is not intended to interfere with standard medical practices for handling anemia. Information on laboratory values including target and achieved hemaglobin (Hb) levels during chemotherapy cycles, use of blood transfusions, iron supplementation, and epoetin will be collected in addition to information on cancer status and treatment. Data on the level that triggers clinicians to decide on the need for anemia therapy will also be collected. Each patient included in the survey will be followed for six months. Observational Study - No investigational drug administered

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Anemic patients with cancer receiving chemotherapy

Inclusion Criteria:

  • Patients with cancer

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01030159

Bangkok, Thailand
Sponsors and Collaborators
Janssen-Cilag Ltd.,Thailand
Study Director: Janssen-Cilag Ltd Clinical Trial Janssen-Cilag Ltd.
  More Information

Responsible Party: Janssen-Cilag Ltd.,Thailand Identifier: NCT01030159     History of Changes
Other Study ID Numbers: CR012703  TCAS-NCI-ONCO-2006 
Study First Received: December 10, 2009
Last Updated: April 8, 2014
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Janssen-Cilag Ltd.,Thailand:
Cancer Anemia Survey
Thai National Cancer Institute

Additional relevant MeSH terms:
Hematologic Diseases processed this record on May 24, 2016